Efficacy and Safety of the Arsenic Trioxide/Lipiodol Emulsion in the Transcatheter Arterial Chemoembolization Combined with Apatinib in the Treatment of Advanced Hepatocellular Carcinoma

Figure 3

(a) Comparison of PFS between patients with PVTT (present) and without PVTT (absent) after the combination of aTACE and apatinib therapy. The median PFS was 5.700 months (95% CI: 3.543–11.857) for treatment with PVTT versus 12.200 months (95% CI: 9.733–14.667) for treatment without PVTT (, log-rank test). (b) Comparison of OS between patients with PVTT (present) and without PVTT (absent) after the combination of aTACE and apatinib therapy. The median OS was 12.800 months (95% CI: 10.447–15.153) for treatment with PVTT versus 27.300 months (95% CI: 22.393–32.207) for treatment without PVTT (, log-rank test). The 1-, 2-, and 3-year OS rates in patients with PVTT were 55.1%, 8.5%, and 0.0%, respectively, and the 1-, 2- and 3-year OS rates in patients without PVTT were 94.9%, 63.8%, and 10.6%, respectively. PFS, progression-free survival; OS, overall survival; aTACE, arsenic trioxide transcatheter arterial chemoembolization; PVTT, portal vein tumor thrombus.

(a)

(b)